Chester County News and Community Website
BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX), a company specializing in non-opioid pain management therapies, has announced significant changes to its leadership team amidst ongoing litigation. The company recently …
Virpax Pharmaceuticals Announces Leadership Changes; Gerald Bruce Appointed CEO, Dr. Eric Floyd Named Chairman Read More BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) has recently revealed its financial results for the third quarter ending September 30, 2023, alongside a series of significant developments.
Virpax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Announces New Developments Read More BERYWN, PA — In a significant move that promises to reshape the future of pain management, Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) recently announced its intent to submit an Investigational New …
Virpax Pharmaceuticals’ Envelta Set for Human Trials Following FDA Review: A Potential Game-Changer in Pain Management Read More BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) recently announced that the cooperative research and development agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) to evaluate Virpax’s …
Virpax Pharmaceuticals Announces Extension of CRADA with the U.S. Army Institute of Surgical Research Read More BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) recently announced that Gerald W. Bruce has been appointed as President and CEO of Novvae™ Pharmaceuticals, Virpax’s wholly-owned subsidiary focused solely on …
Gerald W. Bruce Appointed President and CEO of Novvae Pharmaceuticals Read More BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) announced the recent results of two pre-clinical Probudur™ dose escalation studies.
Virpax Pharmaceuticals Announces Results of Probudur Dose Escalation Studies Read More BERWYN, PA — Virpax Pharmaceuticals, Inc.(NASDAQ: VRPX) announced that it will be presenting virtually at the upcoming H.C. Wainwright event from Monday, September 11th through Wednesday, September 13th starting at 7:00 a.m. …
Virpax Pharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference Read More BERWYN, PA — Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) recently announced its financial results for the three months ended June 30, 2023, and other recent developments.
Virpax Pharmaceuticals Reports 2023 Second Quarter Results, Recent Developments Read More BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) announced that it recently filed a new provisional patent application with the United States Patent and Trademark Office (‘USPTO’) entitled “NSAID Formulation …
Virpax Pharmaceuticals Files Provisional Patent Application for NSAID Formulation and Method Read More BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) announced that it recently filed a new provisional patent application with the United States Patent and Trademark Office (‘USPTO’) entitled “Intranasal Delivery” related …
Virpax Pharmaceuticals Files Provisional Patent Application for Intranasal Delivery Read More